Cargando…

Statins in Non-alcoholic Steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) is the primary cause of chronic liver disease. The range is extensive, including hepatocellular carcinoma, cirrhosis, fibrosis, fatty liver, and non-alcoholic steatohepatitis (NASH). NASH is a condition related to obesity, overweight, metabolic syndrome, dia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Torres-Peña, Jose D., Martín-Piedra, Laura, Fuentes-Jiménez, Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652077/ https://www.ncbi.nlm.nih.gov/pubmed/34901236 http://dx.doi.org/10.3389/fcvm.2021.777131

Ejemplares similares

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
por: Zhu, Bo, et al.
Publicado: (2021)

The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients
por: Ganjooei, Narges Ashraf, et al.
Publicado: (2021)

Could Statin Therapy Be Useful in Patients With Coronavirus Disease 2019 (COVID-19)?
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

Undertreatment or Overtreatment With Statins: Where Are We?
por: García-Fernández-Bravo, Irene, et al.
Publicado: (2022)

Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
por: Ahsan, Farah, et al.
Publicado: (2020)

Hydrophilic or Lipophilic Statins?
por: Climent, Elisenda, et al.
Publicado: (2021)

Cerebrovascular Disease and Statins
por: Beltrán Romero, Luis M., et al.
Publicado: (2021)

Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
por: Bardolia, Chandni, et al.
Publicado: (2021)

Hypoxia-Inducible Factors as Key Players in the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Holzner, Lorenz M. W., et al.
Publicado: (2021)

Statins and Peripheral Arterial Disease: A Narrative Review
por: Jansen-Chaparro, Sergio, et al.
Publicado: (2021)

Targeting acid ceramidase ameliorates fibrosis in mouse models of non-alcoholic steatohepatitis
por: Yu, Amy, et al.
Publicado: (2022)

13 CHEMOPREVENTIVE EFFECT OF STATIN ON HEPATOCELLULAR CARCINOMA IN NON-ALCOHOLIC STEATOHEPATITIS PATIENTS WITH CIRRHOSIS
por: Al-Yaman, Wael A., et al.
Publicado: (2021)

U-Shaped Relationship of Non-HDL Cholesterol With All-Cause and Cardiovascular Mortality in Men Without Statin Therapy
por: Zeng, Rui-Xiang, et al.
Publicado: (2022)

Statin Therapy in Very Old Patients: Lights and Shadows
por: Cobos-Palacios, Lidia, et al.
Publicado: (2021)

Tackling statin intolerance with n-of-1 trials (TaSINI) in primary care: protocol for a feasibility randomised trial to increase statin adherence
por: Tudor, Kate, et al.
Publicado: (2020)

Adverse drug reactions of non-statin antihyperlipidaemic drugs in China from 1989 to 2019: a national database analysis
por: Tsui, Leo, et al.
Publicado: (2023)

Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism
por: Vuorio, Alpo, et al.
Publicado: (2021)

Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews
por: Byrne, Paula, et al.
Publicado: (2019)

Targets of statins intervention in LDL-C metabolism: Gut microbiota
por: Sun, ChangXin, et al.
Publicado: (2022)

The effect of non-optimal lipids on the progression of coronary artery calcification in statin-naïve young adults: results from KOICA registry
por: Lee, Heesun, et al.
Publicado: (2023)

Statin associated adverse reactions in Latin America: a scoping review
por: Urina-Jassir, Manuel, et al.
Publicado: (2021)

Time trends in statin utilisation and coronary mortality in Western European countries
por: Vancheri, Federico, et al.
Publicado: (2016)

In situ assessment of statins’ effect on autophagic activity in zebrafish larvae cardiomyocytes
por: Zhang, Jie, et al.
Publicado: (2022)

Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care
por: Herrett, Emily, et al.
Publicado: (2017)

Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics
por: Sánchez-Fuentes, Ana, et al.
Publicado: (2022)

Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort study
por: Nguyen, Cu Dinh, et al.
Publicado: (2013)

The effect of statins on average survival in randomised trials, an analysis of end point postponement
por: Kristensen, Malene Lopez, et al.
Publicado: (2015)

Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis
por: Nayak, Agnish, et al.
Publicado: (2018)

Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study
por: Kouhpeikar, Hamideh, et al.
Publicado: (2022)

C-reactive protein and statins in heart failure with reduced and preserved ejection fraction
por: Park, Jin Joo, et al.
Publicado: (2022)

Image of Statin-Induced Rhabdomyolysis
por: Kim, Min Chul, et al.
Publicado: (2020)

Statin therapy in multimorbid older patients with polypharmacy- a cross-sectional analysis of the Swiss OPERAM trial population
por: Adam, Luise, et al.
Publicado: (2023)

Statin prescribing for people with severe mental illnesses: a staggered cohort study of ‘real-world’ impacts
por: Blackburn, R, et al.
Publicado: (2017)

A Novel Non-Invasive Approach Based on Serum Ceruloplasmin for Identifying Non-Alcoholic Steatohepatitis Patients in the Non-Diabetic Population
por: Wang, Qingling, et al.
Publicado: (2022)

Association between statin use and the prognosis of patients with acute myocardial infarction complicated with diabetes
por: Lu, Xuehao, et al.
Publicado: (2022)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
por: Wang, Shuai, et al.
Publicado: (2022)

Wildfire smoke exposure and cardiovascular disease—should statins be recommended to prevent cardiovascular events?
por: Vuorio, Alpo, et al.
Publicado: (2023)

Statins Increase Mitochondrial and Peroxisomal Fatty Acid Oxidation in the Liver and Prevent Non-Alcoholic Steatohepatitis in Mice
por: Park, Han-Sol, et al.
Publicado: (2016)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ie7oo904puld14f9uugb4bk3es